Brief Report of Variants Detected in Hereditary Hearing Loss Cases in Iran over a 3-Year Period

Niloofar BAZAZADEGAN¹, Raheleh VAZEHAN², Mahsa FADAEE², Zohreh FATTahi¹, Ayda ABOLHASSANI², Elham PARSIMEHR², Zahra KALHOR², Mehrshid FARAJI ZONOOZ², Fatemeh AHANGARI², Shima DEHDAHSI², Farshide SAMIEE³, Payman JAMALI⁴, Haleh HABIBI⁵, Younes NOURIZADEH⁶, Shokouh MAHDAVI⁷, Maryam BEHESHTIAN¹, Ariana KARIMINEJAD², Richard JH SMITH⁸, *Hossein NAJMABADI²

¹. Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
². Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran
³. Genetic Medical Counseling Center, Qazvin, Iran
⁴. Shabrood Genetic Counseling Center, Welfare Office, Shabrood, Iran
⁵. Genetic Counseling Center, Family Health Clinic, Mobasher Hospital, Hamedan, Iran
⁶. Genetic Counseling Center Welfare Organization, Ilam, Iran
⁷. Welfare Institution Genetic Office, Tehran, Iran
⁸. Department of Otolaryngology-Head and Neck Surgery, Molecular Otolaryngology & Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, IA, USA

*Corresponding Author: Email: hnajm12@yahoo.com

(Received 10 Apr 2018; accepted 19 Jul 2018)

Abstract
Background: Diagnosis of hereditary hearing loss (HHL) as a heterogeneous disorder is very important especially in countries with high rates of consanguinity where the autosomal recessive pattern of inheritance is prevalent. Techniques such as next-generation sequencing, a comprehensive genetic test using targeted genomic enrichment and massively parallel sequencing (TGE + MPS), have made the diagnosis more cost-effective. The aim of this study was to determine HHL variants with comprehensive genetic testing in our country.

Methods: Fifty GJB2 negative individuals with HHL were referred to the Kariminejad-Najmabadi Pathology and Genetics Center, Tehran, one of the reference diagnostic genetic laboratories in Iran, during a 3-year period between 2014 and 2017. They were screened with the OtoSCOPE test, the targeted genomic enrichment and massively parallel sequencing (TGE + MPS) platform after a detailed history had been taken along with clinical evaluation.

Results: Among 32 out of 50 GJB2 negative patients (64%), 34 known pathogenic and novel variants were detected of which 16 (47%) were novel, identified in 10 genes of which the most prevalent were CDH23, MYO7A and MYO15A.

Conclusion: These results provide a foundation from which to make appropriate recommendations for the use of comprehensive genetic testing in the evaluation of Iranian patients with hereditary hearing loss.

Keywords: OtoSCOPE; Hereditary hearing loss; Novel variant; Known variant
Introduction

Genetic causes underlie up to 80% of prelingual hearing loss, one of the most prevalent birth defects (1). To date, more than 150 loci, i.e. about 90 genes, have been reported in non-syndromic hearing loss (http://www.hereditaryhearingloss.org). Iran has a heterogeneous population with a high rate of consanguineous marriages (2). Such populations can be considered to be unique resources of recessive rare genetic disorders. Although HHL is not an uncommon defect, the genetic heterogeneity makes many gene-specific HL types quite rare (3). With regard to the high rate of consanguinity in Iran, which increases the risk of recurrence of autosomal recessive forms of genetic disorders such as deafness, GJB2 mutations are the most prevalent cause of HL among several genes related to autosomal recessive non-syndromic hearing loss (ARNSHL) (4-6). Other AR genes which are in the high prevalence category are SLC26A4, MYO15A, MYO7A, CDH23, and PCDH15 (7).

The fact that early diagnosis in HHL cases may be helpful in prevention and treatment elucidates the need to find the most efficient and cost-effective way to investigate the genetic causes of HL in every population. Hence, this report represents our experience of investigating 50 GJB2 negative HL cases using the OtoSCOPE test, which can screen all the genes involved in hearing loss at once.

Materials and Methods

Fifty GJB2 negative individuals with HHL were referred to the Kariminejad-Najmabadi Pathology and Genetics Center, Tehran, one of the reference diagnostic genetic laboratories in Iran, during a 3-year period between 2014 and 2017. Their detailed history was taken along with a clinical evaluation. All patients completed consent forms and their family pedigrees were drawn to determine the pattern of inheritance.

Hearing thresholds were measured by pure-tone audiometry following standard protocols (8). The targeted genomic enrichment and massively parallel sequencing (TGE + MPS) platform was updated from v6 to v8 as part of our standard operating procedure, increasing the number of genes screened from 116 to 152, using custom-designed Sure Design capture technology (Agilent Technologies, Santa Clara, CA, USA). All data were filtered and analyzed using a variety of in silico mutation prediction programs including Phylop, SIFT, LRT, Mutation taster, PolyPhen (HDIV) and GERP (9). Annotated variants were also considered from the Deafness Variation Database (deafnessvariationdatabase.org).

All results were discussed at a multidisciplinary meeting. The variants in each patient were discussed individually and, in the context of unique clinical information, the most comprehensive diagnosis was provided. Positive results were confirmed via Sanger sequencing before reporting.

Results

Overall, 50 individuals with HHL were enrolled. About 30% of probands had prelingual HL with non-syndromic phenotype. After data analysis, 34 HHL variants were detected in 32 out of the 50 individuals (Table 1) while 18 did not show any hearing loss related variants. The causal variant was detected in 24 out of 33 consanguineous cases. Sixteen new variants were detected among all HL related variants in this study. Four patients had retinitis pigmentosa (RP) with HL in three causative genes, MYO7A, CDH23 and USH2A, with novel and known variants. Auditory neuropathy was associated with one novel variant in the OTOF gene (Table 1).
<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Consent/Genotype</th>
<th>Gene</th>
<th>Nucleotide change</th>
<th>Protein change</th>
<th>Zygosity</th>
<th>Probability of Detecting a Gene/Genotype</th>
<th>OnSCOPE version</th>
<th>Observed features</th>
<th>Reported phenotype(s)</th>
<th>Known/Novel (Reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D68 1912 567</td>
<td>Yes</td>
<td>MYO7A</td>
<td>c.1780C&gt;T</td>
<td>p.Arg570*</td>
<td>Homozygous</td>
<td>4/5</td>
<td>V6</td>
<td>HL</td>
<td>Deafness, autosomal dominant 11 Deafness [MIM# 601317]; autosomal recessive 2 [MIM#6069060]; Usher syndrome; type 1B [MIM#276900]</td>
<td>Known variant (10)</td>
</tr>
<tr>
<td>D79 212</td>
<td>Yes</td>
<td>MYO7A</td>
<td>c.1780C&gt;T</td>
<td>p.Arg570*</td>
<td>Homozygous</td>
<td>4/5</td>
<td>V7</td>
<td>HL</td>
<td>Known variant (10)</td>
<td></td>
</tr>
<tr>
<td>D79 453</td>
<td>No</td>
<td>MYO7A</td>
<td>c.3213C&gt;T</td>
<td>p.Arg1071*</td>
<td>Homozygous</td>
<td>4/5</td>
<td>V7</td>
<td>HL</td>
<td>Known variant (11)</td>
<td></td>
</tr>
<tr>
<td>D72 929</td>
<td>Yes</td>
<td>MYO7A</td>
<td>c.3564_3570delTGCCGG</td>
<td>c.5567delG</td>
<td>Homozygous</td>
<td>ND</td>
<td>V6</td>
<td>HL</td>
<td>Known variant (12)</td>
<td></td>
</tr>
<tr>
<td>D78 454</td>
<td>Yes</td>
<td>MYO7A</td>
<td>c.1845G&gt;Profs*23</td>
<td>p.Tyr1188*</td>
<td>Homozygous</td>
<td>ND</td>
<td>V7</td>
<td>HL+CHD</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D82 779</td>
<td>Yes</td>
<td>MYO7A</td>
<td>c.6028C&gt;T</td>
<td>p.Arg2010Tyr</td>
<td>Homozygous</td>
<td>6/6</td>
<td>V7</td>
<td>HL+RP</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D87 273</td>
<td>No</td>
<td>SLC26A4</td>
<td>c.7382IG &gt;C</td>
<td>p.Met2479Thr</td>
<td>Homozygous/ Heterozygous</td>
<td>ND</td>
<td>V6</td>
<td>HL+RP</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D83 292</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.3491delG</td>
<td>p.Leu1166TrpfsT</td>
<td>Homozygous</td>
<td>ND</td>
<td>V6</td>
<td>HL+RP</td>
<td>Deafness; autosomal recessive 12 [MIM#601386]; Usher syndrome; type 1D; Usher syndrome, type 1D/F digenic [MIM#601607]</td>
<td>Known variant (13)</td>
</tr>
<tr>
<td>D83 195</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.4562A&gt;G</td>
<td>p.Asn1521Ser</td>
<td>Homozygous</td>
<td>5/6</td>
<td>V7</td>
<td>HL</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D80 835</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.2897G&gt;A</td>
<td>p.Arg966His</td>
<td>Homozygous</td>
<td>6/6</td>
<td>V7</td>
<td>HL</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D86 014</td>
<td>No</td>
<td>CDH23</td>
<td>c.1064C&gt;A</td>
<td>p.Thr355Asn</td>
<td>Homozygous</td>
<td>5/6</td>
<td>V8</td>
<td>HL</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D79 686</td>
<td>No</td>
<td>MYO7A</td>
<td>c.3958C&gt;G</td>
<td>p.Ser1319Cys</td>
<td>Homozygous</td>
<td>5/5</td>
<td>V7</td>
<td>HL</td>
<td>Deafness, autosomal recessive 3 [MIM#6003316]</td>
<td>Novel</td>
</tr>
<tr>
<td>D86 357</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.9437A&gt;C</td>
<td>p.His3146Pro</td>
<td>Homozygous</td>
<td>3/5</td>
<td>V8</td>
<td>HL</td>
<td>Known variant (15)</td>
<td></td>
</tr>
<tr>
<td>D88 377</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.13792C&gt;T</td>
<td>p.Glu4598Lys</td>
<td>Homozygous</td>
<td>ND</td>
<td>V6</td>
<td>HL</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D86 627</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.1033C&gt;T</td>
<td>p.Arg345*</td>
<td>Homozygous</td>
<td>2/4</td>
<td>V8</td>
<td>HL</td>
<td>Deafness, autosomal recessive 105 [MIM#616958]</td>
<td>Novel</td>
</tr>
<tr>
<td>D87 240</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.1212G&gt;T</td>
<td>p.Arg376*</td>
<td>Homozygous</td>
<td>3/4</td>
<td>V8</td>
<td>HL</td>
<td>Known variant (18)</td>
<td></td>
</tr>
<tr>
<td>D75 154</td>
<td>No</td>
<td>OTOF</td>
<td>c.1981dupG</td>
<td>p.Arg661Glyfs*2</td>
<td>Homozygous</td>
<td>ND</td>
<td>V6</td>
<td>HL</td>
<td>Auditory neuropathy, autosomal recessive, 1; Deafness, autosomal recessive 9 [MIM#601071]</td>
<td>Known variant (19)</td>
</tr>
<tr>
<td>D79 455</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.2690G&gt;A</td>
<td>p.His894Arg</td>
<td>Homozygous</td>
<td>6/6</td>
<td>V7</td>
<td>HL</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D85 222</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.1228C&gt;A</td>
<td>p.Arg409His</td>
<td>Homozygous</td>
<td>6/6</td>
<td>V8</td>
<td>HL</td>
<td>Deafness, autosomal recessive 4, with enlarged vestibular aqueduct [MIM#600791]; Pendred syndrome [MIM#274600]</td>
<td>Known variant (20)</td>
</tr>
<tr>
<td>D88 275</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.882_886delG</td>
<td>p.His294GlnfsTer35</td>
<td>Homozygous</td>
<td>ND</td>
<td>V8</td>
<td>HL</td>
<td>Novel</td>
<td></td>
</tr>
<tr>
<td>D79 301</td>
<td>No</td>
<td>PAX3</td>
<td>-Deletion of exons 1-4</td>
<td>-</td>
<td>Heterozygous</td>
<td>ND</td>
<td>V7</td>
<td>HL</td>
<td>Craniofacial-deafness-hand syndrome [MIM#122880]; Waardenburg syndrome, type 1 [MIM#193500]; type 3 [MIM#148820]</td>
<td>Known variant (21)</td>
</tr>
<tr>
<td>D84 787</td>
<td>Yes</td>
<td>COL4A1</td>
<td>c.596delC</td>
<td>p.Thr323Hisfs*9</td>
<td>Homozygous</td>
<td>ND</td>
<td>V7</td>
<td>HL</td>
<td>Deafness, autosomal recessive 53 [MIM#601667]; Deafness, autosomal dominant 13 [MIM#601668]; Otophonylogeusphysal dystrophy, autosomal dominant [MIM#188444]; Otophonylogeusphysal dystrophy, autosomal recessive [MIM#215589]</td>
<td>Novel</td>
</tr>
<tr>
<td>D68 163</td>
<td>No</td>
<td>AHM1</td>
<td>c.1246C&gt;T</td>
<td>p.Arg422Trp</td>
<td>Homozygous</td>
<td>3/3</td>
<td>V6</td>
<td>HL</td>
<td>Deafness, X-linked 5 [MIM#300614]</td>
<td>Known variant (22)</td>
</tr>
<tr>
<td>D73 555</td>
<td>Yes</td>
<td>TMC1</td>
<td>Duplication of exons 9-12</td>
<td>-</td>
<td>Homozygous</td>
<td>ND</td>
<td>V7</td>
<td>HL</td>
<td>Known variant (23)</td>
<td></td>
</tr>
<tr>
<td>D88 396</td>
<td>Yes</td>
<td>KIR3</td>
<td>c.1097G&gt;C</td>
<td>p.Cys366Ser</td>
<td>Homozygous</td>
<td>5/6</td>
<td>V8</td>
<td>HL</td>
<td>Known variant (24)</td>
<td></td>
</tr>
<tr>
<td>D96 742</td>
<td>Yes</td>
<td>TMPRSS5</td>
<td>c.1211C&gt;T</td>
<td>p.Pro404Leu</td>
<td>Homozygous</td>
<td>6/6</td>
<td>V8</td>
<td>HL</td>
<td>Known variant (25)</td>
<td></td>
</tr>
<tr>
<td>D88 130</td>
<td>Yes</td>
<td>CDH23</td>
<td>c.1498C&gt;T</td>
<td>p.Arg499Ter</td>
<td>Homozygous</td>
<td>2/4</td>
<td>V8</td>
<td>HL</td>
<td>Deafness, autosomal recessive 49 [MIM#610153]</td>
<td>Known variant (26)</td>
</tr>
</tbody>
</table>

HL, Hearing loss; CHD, Congenital heart defect; RP, Retinitis pigmentosa; MIM, Mendelian Inheritance in Man; ND, Not determined

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
Variants with pathogenicity score were checked using a maximum of six computational methods (Phylop, SIFT, LRT, Mutation taster, PolyPhen-HDIV and GERP) to study conservation of missense variants and functional significance.

Discussion

In the present study, 50 individuals with HHL were studied. Because of the heterogeneity and the role of different loci and genes in HHL, an affordable technique was required to minimize the cost and time needed for diagnosis. OtoSCOPE was chosen for detection of causative variants related to hearing loss as it can screen all the genes involved in hearing loss at once. After evaluating with this test, 16 known variants were detected in 16 individuals in whom four showed retinitis pigmentosa (RP) and hearing loss with homozygous and compound heterozygous variants in MYO7A, CDH23 and USH2A genes. Twelve genes are known to cause Usher syndrome (26). In this study, only three causative genes, MYO7A, CDH23 and USH2A with novel and known variants contributed to both RP and hearing loss. Two of these genes, MYO7A and CDH23, are among five genes involved in neuro-sensory hearing loss (26). Mutations in the MYO15A gene were seen in three affected individuals. Deficiency in the protein encoded by the MYO15A gene results in severe to profound congenital non-syndromic hearing loss (27).

Our patients with MYO15A gene mutations also had severe to profound phenotype. The first MYO15A mutations causing ARNSHL was reported in the Iranian population and believed this mutation to be a common cause of ARNSHL (28). Recently, MYO15A mutations accounted for 9.6% of HL in a study on 302 Iranian families affected by ARNSHL (3). In our study, 3/50 affected individuals had MYO15A gene mutations in which four novel and known variants were detected. This is very similar to other findings (29). One novel variant in the USH2A gene was detected in one individual, and one novel and one known variant were also detected in the PAX3 and MITF genes, respectively, in two persons with Waardenburg syndrome and profound HL. Waardenburg syndrome is one of the most prevalent forms of autosomal dominant syndromic hearing loss (ADSHL) in Iran. It may account for 1%-4% of severe-to-profound HL (30). Recently, PAX3 mutations were reported in a group of Iranian patients with this syndrome (31). In our study MYO7A, CDH23, MYO15A and USH2A genes were the most prevalent genes with known and novel variants. Other genes with a high rate of mutations were CDC14A, OTOF and SLC26A4.

In our clinical diagnostic laboratory, we were able to diagnose a genetic cause of deafness in 32 out of 50 persons (64%). This rate ranged from 10% to 83% in several small cohort studies (32). This perhaps reflects the higher coefficient of inbreeding in our population, as in other populations with Middle Eastern ethnicity, where the diagnostic rate is higher (72%) (33). Other patients had no hearing loss related mutations, perhaps indicating the presence of other rare causative genes identified with future whole exome or whole-genome sequencing.

Conclusion

Platforms such as OtoSCOPE, providing comprehensive genetic screening for deafness, will allow clinicians to improve patient care by providing prognostic information, and in cases with both RP and hearing loss, offer families preventative strategies to minimize the rate of progression of retinitis pigmentosa.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

We would like to thank all the families included in this study for their time and generosity in supplying personal data.

Conflict of interest

The authors declare that there is no conflict of interests.

Available at:  http://ijph.tums.ac.ir
References


Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)